Pediatric Zollinger-Ellison Syndrome Clinical Presentation
- Author: Stefano Guandalini, MD; Chief Editor: Carmen Cuffari, MD more...
History and Physical Examination
The typical presentation of Zollinger-Ellison syndrome (ZES) is severe abdominal pain, with or without diarrhea. Most children present with complications of peptic ulcer disease (PUD), such as bleeding from an ulcer or duodenal perforation.
Abdominal pain
The abdominal pain is due to peptic ulcers, which can be found in the upper gastrointestinal (GI) tract in 90-95% of patients. These ulcers are often multiple (see the following image) or in unusual locations. In 70% of patients, single or multiple ulcers are found in the first part of the duodenum. However, ulcers in the second or third part of the duodenum or in the jejunum are highly suggestive of Zollinger-Ellison syndrome. Other characteristics of Zollinger-Ellison syndrome ulcers include a size larger than 2 cm and a refractory behavior to conventional therapy.
Diarrhea
The second most common symptom of Zollinger-Ellison syndrome ulcers is diarrhea, which is seen in 50-65% of patients. Diarrhea may be the only symptom; however, it can also precede or follow the ulcer formation. The diarrhea is due to mucosal damage by activated pepsinogens that result from excessive acid secretion. Other mechanisms of diarrhea in Zollinger-Ellison syndrome include inhibition of sodium and water absorption, bile acid insolubility, and inactivation of pancreatic enzymes, leading to both malabsorptive (steatorrhea) and secretory states.[10]
Other symptoms
Zollinger-Ellison syndrome may also manifest as symptoms of gastroesophageal reflux and, in severe cases, has been associated with esophageal stenosis or Barrett mucosa in adults.
Because Zollinger-Ellison may present with many vague, common GI symptoms, the correct diagnosis is often delayed by 4-6 years.[11, 12]
Physical findings
The physical examination findings in affected patients are often normal. These children may have abdominal tenderness and, in the case of perforation, they may have peritoneal signs. Patients who experience anemia due to bleeding ulcers may appear pale and may have tachycardia and/or fatigue.
Staging
Staging Zollinger-Ellison syndrome (ZES) is based on tumor size (>2-3 cm) and metastases to the lymph nodes, liver, or both. Metastases to the liver are associated with poor prognosis and have been reported to occur in roughly 60% of patients with pancreatic gastrinoma versus less than 10% in patients with duodenal gastrinoma.[13]
Tumor size does not relate to serum gastrin levels or the severity of symptoms.
Ectopic Cushing syndrome, tumor flow cytometry features, and overexpression of certain growth factors such as human epidermal growth factor receptor 2 (HER2/neu) are associated with aggressive gastrinomas and poor prognosis.
Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore). Jan 2004;83(1):43-83. [Medline].
Imamura M, Komoto I, Ota S. Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome. World J Surg. Jan 2006;30(1):1-11. [Medline].
Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. Oct 1955;142(4):709-23; discussion, 724-8. [Medline]. [Full Text].
Passaro E, Howard TJ, Sawicki MP, et al. The origin of sporadic gastrinomas within the gastrinoma triangle: a theory. Arch Surg. Jan 1998;133(1):13-6; discussion 17. [Medline].
Debelenko LV, Emmert-Buck MR, Zhuang Z, et al. The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology. Sep 1997;113(3):773-81. [Medline].
Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. Mar 18 1999;340(11):858-68. [Medline].
Evans JT, Nickles S, Hoffman BJ. Primary hepatic gastrinoma: an unusual case of zollinger-ellison syndrome. Gastroenterol Hepatol (N Y). Jan 2010;6(1):53-6. [Medline]. [Full Text].
Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. Aug 26 1999;341(9):635-44. [Medline].
Nord KS, Joshi V, Hanna M, et al. Zollinger-Ellison syndrome associated with a renal gastrinoma in a child. J Pediatr Gastroenterol Nutr. Nov-Dec 1986;5(6):980-6. [Medline].
Morrow EH, Norton JA. Surgical management of Zollinger-Ellison syndrome; state of the art. Surg Clin North Am. Oct 2009;89(5):1091-103. [Medline].
Eire PF, Rodriguez Pereira C, Barca Rodriguez P, Varela Cives R. Uncommon case of gastrinoma in a child. Eur J Pediatr Surg. Jun 1996;6(3):173-4. [Medline].
Ito T, Jensen RT. Primary hepatic gastrinoma: an unusual case of zollinger-ellison syndrome. Gastroenterol Hepatol (N Y). Jan 2010;6(1):57-9. [Medline]. [Full Text].
Heikenen JB, Pohl JF, Werlin SL. Octreotide in pediatric patients. J Pediatr Gastroenterol Nutr. Nov 2002;35(5):600-9. [Medline].
Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). Nov 2006;85(6):295-330. [Medline].
Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore). Nov 2006;85(6):331-64. [Medline].
Proye C, Malvaux P, Pattou F, et al. Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery. Dec 1998;124(6):1134-43; discussion 1143-4. [Medline].
Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. Dec 2004;136(6):1267-74. [Medline].
Corleto VD, Annibale B, Gibril F, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?. Aliment Pharmacol Ther. Oct 2001;15(10):1555-61. [Medline].
Jensen RT. Gastrinomas: Advances in Diagnosis and Management. Neuroendocrinology. 2004;80 Suppl 1:23-27. [Medline].
Kwekkeboom DJ, de Herder WW, van Eijck CH, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. Mar 2010;40(2):78-88. [Medline].
Mozell EJ, Cramer AJ, O'Dorisio TM, Woltering EA. Long-term efficacy of octreotide in the treatment of Zollinger-Ellison syndrome. Arch Surg. Sep 1992;127(9):1019-24; discussion 1024-6. [Medline].
Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab. May 2008;93(5):1582-91. [Medline].
Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg. Jan 2009;46(1):13-106. [Medline].
Gibril F, Jensen RT. Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep. May 2005;7(2):114-21. [Medline].
Quatrini M, Castoldi L, Rossi G, et al. A follow-up study of patients with Zollinger-Ellison syndrome in the period 1966-2002: effects of surgical and medical treatments on long-term survival. J Clin Gastroenterol. May-Jun 2005;39(5):376-80. [Medline].
Tomassetti P, Campana D, Piscitelli L, et al. Treatment of Zollinger-Ellison syndrome. World J Gastroenterol. Sep 21 2005;11(35):5423-32. [Medline]. [Full Text].

